These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 7603215

  • 1. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ, Wirin D, Shaked A, Busuttil RW.
    Lancet; 1995 Jul 08; 346(8967):69-74. PubMed ID: 7603215
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 3. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 27; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 4. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH.
    Transplantation; 1998 Dec 27; 66(12):1780-6. PubMed ID: 9884276
    [Abstract] [Full Text] [Related]

  • 5. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
    Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T.
    Ann Intern Med; 1994 Mar 01; 120(5):375-81. PubMed ID: 8304654
    [Abstract] [Full Text] [Related]

  • 6. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.
    Transplantation; 1998 Dec 27; 66(12):1682-8. PubMed ID: 9884259
    [Abstract] [Full Text] [Related]

  • 7. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.
    Martin M, Mañez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ondick L, Ptachcinski R, Irish W, Kisor D.
    Transplantation; 1994 Oct 15; 58(7):779-85. PubMed ID: 7940710
    [Abstract] [Full Text] [Related]

  • 8. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
    Turgeon N, Fishman JA, Doran M, Basgoz N, Tolkoff-Rubin NE, Cosimi AB, Rubin RH.
    Transpl Infect Dis; 2000 Mar 15; 2(1):2-10. PubMed ID: 11429003
    [Abstract] [Full Text] [Related]

  • 9. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.
    Transplantation; 1997 Jul 15; 64(1):66-73. PubMed ID: 9233703
    [Abstract] [Full Text] [Related]

  • 10. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S, Faulds D.
    Drugs; 1998 Jul 15; 56(1):115-46. PubMed ID: 9664203
    [Abstract] [Full Text] [Related]

  • 11. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
    Yango A, Morrissey P, Zanabli A, Beaulieu J, Shemin D, Dworkin L, Monaco A, Gohh R.
    Nephrol Dial Transplant; 2003 Apr 15; 18(4):809-13. PubMed ID: 12637653
    [Abstract] [Full Text] [Related]

  • 12. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT, Tsapepas DS, Li H, Anamisis A, Martin ST.
    Prog Transplant; 2015 Mar 15; 25(1):39-44. PubMed ID: 25758799
    [Abstract] [Full Text] [Related]

  • 13. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ, Busuttil RW.
    Transplantation; 2004 Jan 27; 77(2):305-8. PubMed ID: 14742998
    [Abstract] [Full Text] [Related]

  • 14. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children.
    Green M, Kaufmann M, Wilson J, Reyes J.
    Clin Infect Dis; 1997 Dec 27; 25(6):1344-9. PubMed ID: 9431375
    [Abstract] [Full Text] [Related]

  • 15. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec 27; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD.
    Am J Kidney Dis; 2002 May 27; 39(5):1088-95. PubMed ID: 11979354
    [Abstract] [Full Text] [Related]

  • 17. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
    Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA.
    Lancet; 1997 Dec 13; 350(9093):1729-33. PubMed ID: 9413463
    [Abstract] [Full Text] [Related]

  • 18. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
    Ginevri F, Losurdo G, Fontana I, Rabagliati AM, Bonatto L, Valente R, Venzano P, Nocera A, Basile GC, Valente U, Gusmano R.
    Transpl Int; 1998 Dec 13; 11 Suppl 1():S130-4. PubMed ID: 9664962
    [Abstract] [Full Text] [Related]

  • 19. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 13; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 20. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T, Opatrny K, Bouda M, Treska V, Jindra P, Svecova M.
    Transpl Int; 2002 Dec 13; 15(12):615-22. PubMed ID: 12478408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.